المؤلفون: Soltani J., Kovacevic T., Nielsen J.P., Petersen J.R., Poorisrisak P., Jensen L.H., Laan M., Tamm E., Matsinen M., Rummukainen M.-L., Gajdos V., Olivier R., Le Marechal F., Martinot A., Prot-Labarthe S., Lorrot M., Orbach D., Pagava K., Hufnagel M., Knuf M., Schlag S.A.A., Liese J., Renner L., Enimil A., Awunyo M., Syridou G., Spyridis N., Critselis E., Kouni S., Mougkou K., Ladomenou F., Gkentzi D., Iosifidis E., Roilides E., Sahu S., Murki S., Malviya M., Kalavalapalli D.B., Singh S., Singhal T., Garg G., Garg P., Kler N., Jafarpour Z., Pouladfar G., Nicolini G., Montagnani C., Galli L., Esposito S., Vecchio A.L., Dona' D., Giaquinto C., Borgia E., D'Argenio P., De Luca M., Centenari C., Raka L., Omar A., Al-Mousa H., Mozgis D., Sviestina I., Burokiene S., Usonis V., Tavchioska G., Hargadon-Lowe A., Zarb P., Borg M.A., Gonzalez Lozano C.A., Castanon P.Z., Cancino M.E., McCullagh B., McCorry A., Gormley C., Al Maskari Z., Al-Jardani A., Pluta M., Rodrigues F., Brett A., Esteves I., Marques L., AlAjmi J.A., Cambrea S.C., Rashed A.N., Al Azmi A.A.M., Chan S.M., Isa M.S., Najdenov P., Cizman M., Unuk S., Finlayson H., Dramowski A., Mate-Cano I., Soto B., Calvo C., Santiago B., Saavedra-Lozano J., Bustinza A., Escosa-Garcia L., Ureta N., Tagarro A., Barrero P.T., Rincon-Lopez E.M., Abubakar I., Aston J., Heginbothom M., Satodia P., Garbash M., Johnson A., Sharpe D., Barton C., Menson E., Arenas-Lopez S., Luck S., Doerholt K., McMaster P., Caldwell N.A., Lunn A., Drysdale S.B., Howe R., Scorrer T., Gahleitner F., Gupta R., Nash C., Alexander J., Raman M., Bell E., Rajagopal V., Kohlhoff S., Cox E., Zaoutis T., Versporten A., Bielicki J., Drapier N., Sharland M., Goossens H., Calle G.M., Clark J., Cooper C., Blyth C.C., Francis J.R., Alsalman J., Jansens H., Mahieu L., Van Rossom P., Vandewal W., Lepage P., Blumental S., Briquet C., Robbrecht D., Maton P., Gabriels P., Rubic Z.

مصطلحات الفهرس: flucloxacillin/ad [Drug Administration], cefuroxime/dt [Drug Therapy], chloramphenicol/ad [Drug Administration], chloramphenicol/dt [Drug Therapy], ciprofloxacin/ad [Drug Administration], ciprofloxacin/dt [Drug Therapy], clarithromycin/ad [Drug Administration], clarithromycin/dt [Drug Therapy], clindamycin/ad [Drug Administration], clindamycin/dt [Drug Therapy], cloxacillin/ad [Drug Administration], cloxacillin/dt [Drug Therapy], cotrimoxazole/ad [Drug Administration], cotrimoxazole/dt [Drug Therapy], flucloxacillin/dt [Drug Therapy], gentamicin/ad [Drug Administration], gentamicin/dt [Drug Therapy], levofloxacin/ad [Drug Administration], levofloxacin/dt [Drug Therapy], meropenem/ad [Drug Administration], meropenem/dt [Drug Therapy], metronidazole/ad [Drug Administration], metronidazole/dt [Drug Therapy], nalidixic acid/ad [Drug Administration], nalidixic acid/dt [Drug Therapy], piperacillin/ad [Drug Administration], piperacillin/dt [Drug Therapy], procaine penicillin/ad [Drug Administration], procaine penicillin/dt [Drug Therapy], teicoplanin/ad [Drug Administration], teicoplanin/dt [Drug Therapy], tobramycin/ad [Drug Administration], tobramycin/dt [Drug Therapy], unindexed drug, vancomycin/ad [Drug Administration], vancomycin/dt [Drug Therapy], Africa, antibiotic resistance, antibiotic therapy, article, Asia, Australia, child, clinical indicator, clinical practice, drug utilization, Europe, health survey, hospital admission, hospital infection/dt [Drug Therapy], human, infection prevention, medical documentation, newborn, North America, prescription, prevalence, South and Central America, amikacin/ad [Drug Administration], amikacin/dt [Drug Therapy], amoxicillin/ad [Drug Administration], amoxicillin/dt [Drug Therapy], ampicillin/ad [Drug Administration], ampicillin/dt [Drug Therapy], azithromycin/ad [Drug Administration], azithromycin/dt [Drug Therapy], cefazolin/ad [Drug Administration], cefazolin/dt [Drug Therapy], cefepime/ad [Drug Administration], cefepime/dt [Drug Therapy], cefoperazone/ad [Drug Administration], cefoperazone/dt [Drug Therapy], ceforanide/ad [Drug Administration], ceforanide/dt [Drug Therapy], cefotaxime/ad [Drug Administration], cefotaxime/dt [Drug Therapy], ceftazidime/ad [Drug Administration], ceftazidime/dt [Drug Therapy], ceftriaxone/ad [Drug Administration], ceftriaxone/dt [Drug Therapy], cefuroxime/ad [Drug Administration], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39657
Journal of Antimicrobial Chemotherapy
Click here for full text options
LibKey Link

المؤلفون: Soltani J., Kovacevic T., Nielsen J.P., Petersen J.R., Poorisrisak P., Jensen L.H., Laan M., Tamm E., Matsinen M., Rummukainen M.-L., Gajdos V., Olivier R., Le Marechal F., Martinot A., Prot-Labarthe S., Lorrot M., Orbach D., Pagava K., Hufnagel M., Knuf M., Schlag S.A.A., Liese J., Renner L., Enimil A., Awunyo M., Syridou G., Spyridis N., Critselis E., Kouni S., Mougkou K., Ladomenou F., Gkentzi D., Iosifidis E., Roilides E., Sahu S., Murki S., Malviya M., Kalavalapalli D.B., Singh S., Singhal T., Garg G., Garg P., Kler N., Jafarpour Z., Pouladfar G., Nicolini G., Montagnani C., Galli L., Esposito S., Vecchio A.L., Dona' D., Giaquinto C., Borgia E., D'Argenio P., De Luca M., Centenari C., Raka L., Omar A., Al-Mousa H., Mozgis D., Sviestina I., Burokiene S., Usonis V., Tavchioska G., Hargadon-Lowe A., Zarb P., Borg M.A., Gonzalez Lozano C.A., Castanon P.Z., Cancino M.E., McCullagh B., McCorry A., Gormley C., Al Maskari Z., Al-Jardani A., Pluta M., Rodrigues F., Brett A., Esteves I., Marques L., AlAjmi J.A., Cambrea S.C., Rashed A.N., Al Azmi A.A.M., Chan S.M., Isa M.S., Najdenov P., Cizman M., Unuk S., Finlayson H., Dramowski A., Mate-Cano I., Soto B., Calvo C., Santiago B., Saavedra-Lozano J., Bustinza A., Escosa-Garcia L., Ureta N., Tagarro A., Barrero P.T., Rincon-Lopez E.M., Abubakar I., Aston J., Heginbothom M., Satodia P., Garbash M., Johnson A., Sharpe D., Barton C., Menson E., Arenas-Lopez S., Luck S., Doerholt K., McMaster P., Caldwell N.A., Lunn A., Drysdale S.B., Howe R., Scorrer T., Gahleitner F., Gupta R., Nash C., Alexander J., Raman M., Bell E., Rajagopal V., Kohlhoff S., Cox E., Zaoutis T., Versporten A., Bielicki J., Drapier N., Sharland M., Goossens H., Calle G.M., Clark J., Cooper C., Blyth C.C., Francis J.R., Alsalman J., Jansens H., Mahieu L., Van Rossom P., Vandewal W., Lepage P., Blumental S., Briquet C., Robbrecht D., Maton P., Gabriels P., Rubic Z.

مصطلحات الفهرس: flucloxacillin/ad [Drug Administration], cefuroxime/dt [Drug Therapy], chloramphenicol/ad [Drug Administration], chloramphenicol/dt [Drug Therapy], ciprofloxacin/ad [Drug Administration], ciprofloxacin/dt [Drug Therapy], clarithromycin/ad [Drug Administration], clarithromycin/dt [Drug Therapy], clindamycin/ad [Drug Administration], clindamycin/dt [Drug Therapy], cloxacillin/ad [Drug Administration], cloxacillin/dt [Drug Therapy], cotrimoxazole/ad [Drug Administration], cotrimoxazole/dt [Drug Therapy], flucloxacillin/dt [Drug Therapy], gentamicin/ad [Drug Administration], gentamicin/dt [Drug Therapy], levofloxacin/ad [Drug Administration], levofloxacin/dt [Drug Therapy], meropenem/ad [Drug Administration], meropenem/dt [Drug Therapy], metronidazole/ad [Drug Administration], metronidazole/dt [Drug Therapy], nalidixic acid/ad [Drug Administration], nalidixic acid/dt [Drug Therapy], piperacillin/ad [Drug Administration], piperacillin/dt [Drug Therapy], procaine penicillin/ad [Drug Administration], procaine penicillin/dt [Drug Therapy], teicoplanin/ad [Drug Administration], teicoplanin/dt [Drug Therapy], tobramycin/ad [Drug Administration], tobramycin/dt [Drug Therapy], unindexed drug, vancomycin/ad [Drug Administration], vancomycin/dt [Drug Therapy], Africa, antibiotic resistance, antibiotic therapy, article, Asia, Australia, child, clinical indicator, clinical practice, drug utilization, Europe, health survey, hospital admission, hospital infection/dt [Drug Therapy], human, infection prevention, medical documentation, newborn, North America, prescription, prevalence, South and Central America, amikacin/ad [Drug Administration], amikacin/dt [Drug Therapy], amoxicillin/ad [Drug Administration], amoxicillin/dt [Drug Therapy], ampicillin/ad [Drug Administration], ampicillin/dt [Drug Therapy], azithromycin/ad [Drug Administration], azithromycin/dt [Drug Therapy], cefazolin/ad [Drug Administration], cefazolin/dt [Drug Therapy], cefepime/ad [Drug Administration], cefepime/dt [Drug Therapy], cefoperazone/ad [Drug Administration], cefoperazone/dt [Drug Therapy], ceforanide/ad [Drug Administration], ceforanide/dt [Drug Therapy], cefotaxime/ad [Drug Administration], cefotaxime/dt [Drug Therapy], ceftazidime/ad [Drug Administration], ceftazidime/dt [Drug Therapy], ceftriaxone/ad [Drug Administration], ceftriaxone/dt [Drug Therapy], cefuroxime/ad [Drug Administration], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39657
Journal of Antimicrobial Chemotherapy
LibKey Link

المؤلفون: Holmes N.E., Korman T.M., Dendle C., Hodgkinson M.

مصطلحات الفهرس: human, immediate type hypersensitivity, letter, Mycobacterium chelonei, priority journal, skin nodule/dt [Drug Therapy], skin nodule/et [Etiology], skin ulcer/dt [Drug Therapy], skin ulcer/et [Etiology], amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/ad [Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/do [Drug Dose], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], doxycycline/ae [Adverse Drug Reaction], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], imipenem/dt [Drug Therapy], imipenem/iv [Intravenous Drug Administration], linezolid/ae [Adverse Drug Reaction], linezolid/dt [Drug Therapy], moxifloxacin/dt [Drug Therapy], rifampicin/dt [Drug Therapy], clinical protocol, absence of side effects/si [Side Effect], aged, anamnesis, antibiotic therapy, bacterial skin disease/dt [Drug Therapy], bacterial skin disease/et [Etiology], case report, desensitization, diarrhea/si [Side Effect], drug choice, drug dose increase, drug substitution, drug withdrawal, female, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31608
Click here for full text options
LibKey Link

المؤلفون: Holmes N.E., Korman T.M., Dendle C., Hodgkinson M.

مصطلحات الفهرس: human, immediate type hypersensitivity, letter, Mycobacterium chelonei, priority journal, skin nodule/dt [Drug Therapy], skin nodule/et [Etiology], skin ulcer/dt [Drug Therapy], skin ulcer/et [Etiology], amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/ad [Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/do [Drug Dose], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], doxycycline/ae [Adverse Drug Reaction], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], imipenem/dt [Drug Therapy], imipenem/iv [Intravenous Drug Administration], linezolid/ae [Adverse Drug Reaction], linezolid/dt [Drug Therapy], moxifloxacin/dt [Drug Therapy], rifampicin/dt [Drug Therapy], clinical protocol, absence of side effects/si [Side Effect], aged, anamnesis, antibiotic therapy, bacterial skin disease/dt [Drug Therapy], bacterial skin disease/et [Etiology], case report, desensitization, diarrhea/si [Side Effect], drug choice, drug dose increase, drug substitution, drug withdrawal, female, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31608
LibKey Link